$1.55 Million in Sales Expected for Albireo Pharma Inc (ALBO) This Quarter
Wall Street analysts expect Albireo Pharma Inc (NASDAQ:ALBO) to report $1.55 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Albireo Pharma’s earnings, with the lowest sales estimate coming in at $700,000.00 and the highest estimate coming in at $3.00 million. The company is expected to announce its next quarterly earnings report on Tuesday, November 13th.
According to Zacks, analysts expect that Albireo Pharma will report full-year sales of $14.62 million for the current year, with estimates ranging from $11.90 million to $18.93 million. For the next fiscal year, analysts expect that the company will post sales of $13.73 million per share, with estimates ranging from $5.00 million to $26.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Albireo Pharma.
Albireo Pharma (NASDAQ:ALBO) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.24). The firm had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $2.00 million.
In other Albireo Pharma news, COO Jan Mattsson sold 25,000 shares of the company’s stock in a transaction on Wednesday, June 13th. The stock was sold at an average price of $32.26, for a total value of $806,500.00. Following the completion of the transaction, the chief operating officer now owns 43,538 shares in the company, valued at approximately $1,404,535.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ronald Harold Wilfred Cooper acquired 788 shares of Albireo Pharma stock in a transaction on Tuesday, August 14th. The stock was acquired at an average price of $31.85 per share, with a total value of $25,097.80. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Federated Investors Inc. PA lifted its position in shares of Albireo Pharma by 89.1% during the 2nd quarter. Federated Investors Inc. PA now owns 586,146 shares of the biopharmaceutical company’s stock valued at $20,808,000 after buying an additional 276,221 shares during the last quarter. Artal Group S.A. lifted its position in shares of Albireo Pharma by 82.6% during the 1st quarter. Artal Group S.A. now owns 547,841 shares of the biopharmaceutical company’s stock valued at $17,843,000 after buying an additional 247,841 shares during the last quarter. BlackRock Inc. lifted its position in shares of Albireo Pharma by 582.8% during the 2nd quarter. BlackRock Inc. now owns 524,276 shares of the biopharmaceutical company’s stock valued at $18,611,000 after buying an additional 447,496 shares during the last quarter. BVF Inc. IL purchased a new position in shares of Albireo Pharma during the 1st quarter valued at $7,328,000. Finally, Millennium Management LLC lifted its position in shares of Albireo Pharma by 234.0% during the 1st quarter. Millennium Management LLC now owns 155,611 shares of the biopharmaceutical company’s stock valued at $5,068,000 after buying an additional 109,017 shares during the last quarter. 63.38% of the stock is currently owned by hedge funds and other institutional investors.
Albireo Pharma stock traded down $0.71 during trading on Friday, hitting $32.42. 763 shares of the company were exchanged, compared to its average volume of 46,181. Albireo Pharma has a 52 week low of $20.25 and a 52 week high of $39.87. The company has a market capitalization of $396.56 million, a P/E ratio of -10.32 and a beta of 1.28.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Featured Article: Technical Analysis of Stocks and What It Means
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.